# Nektar Therapeutics

Type: Company (NKTR)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/nektar-therapeutics
Canonical HTML page: https://getfinancebrief.com/entity/nektar-therapeutics

## Timeline

- **2026-03-22**: Enphase Energy Filing — Pomerantz LLP files a separate class action against Enphase Energy alleging securities fraud.
- **2026-03-22**: Secondary Nektar Notice — A follow-up announcement clarifies the class period and lead plaintiff deadline for Nektar investors.
- **2026-03-21**: Nektar Litigation Announced — Pomerantz LLP announces the first class action filing against Nektar Therapeutics.

## Recent coverage (1 stories)

### Pomerantz LLP Targets Nektar and Enphase in New Securities Class Actions
2026-03-22 02:52:54 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Pomerantz LLP has initiated class action litigation against Nektar Therapeutics and Enphase Energy, alleging securities fraud and misleading statements. These filings highlight a growing trend of legal scrutiny in the biotech and renewable energy sectors as companies navigate volatile market conditions and regulatory shifts.
Full story: https://getfinancebrief.com/story/pomerantz-llp-nektar-enphase-class-action-litigation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.